1. Treatment Prevalence Project Background information Expert meeting Implementation of the treatment strategy – Module 1: TDI prevalence 24 June 2013

2. Aim of the project To have the total number of treatment clients in a country To collect data on the total number of drug addicts reached by treatment To get the number of drug users in treatment for long period or more than one year To have a picture of the profile of the treated population, including its characteristics

3. History of the project (1) May 2005:proposal of the Dutch SC member September 2005:discussion during the TDI expert meeting, NL presentation and setting up a working group November 2005: proposal for a pilot project presented to NFPs January 2006:working group meeting 9 volunteer countries and launch of pilot project Summer 2006:1st pilot data collection Sep.-Nov. 2006presentations first results during the TDI and RTX meeting

4. History of the project (2) Summer 2007:2 nd pilot data collection Summer 2007:feasibility assessment with NFPs Sep.-Nov.2007:presentations results of 2 nd pilot data collection and of the feasibility assessment (TDI and RTX meeting) 2008:3 rd pilot data collection 2008 until 2012:TDI revision: TDI prevalence as separated project 2013:TDI prevalence included in the 2013 Work programme

5. Results from feasibility assessment (2007) 28 countries replied: 25 MS + TK + HR + NO 2 countries not replying: RO, SI Source: Results from a survey to the NFPs on feasibility assessment

6. Reasons for collecting prevalence data (23 countries) More complete information on the whole drug problem Overview of drug treatment population: most part of treatment clients is not included in the current TDI data collection More “realistic” picture on the number of drug clients Useful data for treatment planning: it gives information on treatment capacities and treatment needs Increase research and analysis potentialities with TDI data

7. Reasons for not collecting prevalence data (5 countries – DK, SP, GR, SW, NO) Data collection: low feasibility (3 countries) or not feasible (2 countries) Burden increase in the NFPs and treatment networks Decrease in data quality 50% increase in financial (between 20.000 and 300.000 euros) and human resources (between 3 and 5 staff members) in the implementation phase Less for maintaining the information system Not much added value to the information currently collected

8. Resources to be invested No additional costs for 7 countries Differences in the remaining countries Human resources: between 1 and 8 staff Financial resources:between 20 000 and 100 000 Euros (often including staff cost)

9. Additional feedback from NFPs and TDI experts Agreement on implementing data collection on treatment prevalence Clear definition/methodology needed Only basic data should be collected